Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study



Status:Recruiting
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - Any
Updated:1/16/2019
Start Date:March 23, 2018
End Date:September 29, 2021
Contact:Brian M Ilfeld, MD, MS
Email:bilfeld@ucsd.edu
Phone:(858) 822-0776

Use our guide to learn which trials are right for you!

Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Definitive Human Subjects Clinical Trial

When a limb is severed, pain perceived in the part of the body that no longer exists often
develops and is called "phantom limb" pain. Unfortunately, phantom pain goes away in only 16%
of afflicted individuals, and there is currently no reliable definitive treatment. The exact
reason that phantom limb pain occurs is unclear, but when a nerve is cut-as happens with an
amputation-changes occur in the brain and spinal cord that actually increase with worsening
phantom pain. These abnormal changes may often be corrected by putting local
anesthetic-called a "nerve block"-on the injured nerve, effectively keeping any "bad signals"
from reaching the brain with a simultaneous resolution of the phantom limb pain. However,
when the nerve block resolves after a few hours, the phantom pain returns. But, this
demonstrates that the brain abnormalities-and phantom pain-that occur with an amputation are
not necessarily fixed, and may be dependent upon the "bad" signals being sent from the
injured nerve(s), suggesting that a very long peripheral nerve block-lasting many months
rather than hours-may permanently reverse the abnormal changes in the brain, and provide
definitive relief from phantom pain. A prolonged nerve block lasting a few months may be
provided by freezing the nerve using a process called "cryoneurolysis". The ultimate
objective of the proposed research study is to determine if cryoanalgesia is an effective
treatment for intractable post-amputation phantom limb pain. The proposed research study will
include subjects with an existing lower extremity amputation who experience intractable daily
phantom limb pain. A single ultrasound-guided treatment of cryoneurolysis (or sham
block-determined randomly like a flip of a coin) will be applied to the target nerve(s)
involved with the phantom pain. Although not required, each subject may return four months
later for the alternative treatment (if the first treatment is sham, then the second
treatment would be cryoneurolysis) so that all participants have the option of receiving the
active treatment. Subjects will be followed for a total of 12 months with data collected by
telephone.

Subjects will be asked to make no changes to their analgesic regimen for at least 1 month
prior to the cryoneurolysis procedure and continuing for 4 months until the measurement of
the primary end point-for the duration of the study, all patients will be allowed to continue
their pre-intervention analgesics. All subjects will have a peripheral intravenous catheter
inserted, standard noninvasive monitors applied, and oxygen administered via a facemask or
nasal cannula. Midazolam and fentanyl (IV) will be titrated for patient comfort. The specific
nerves targeted will be the sciatic and femoral (or their distal branches). The potential
cryoneurolysis sites will be cleansed with chlorhexidine gluconate and isopropyl alcohol. The
target nerves will be identified in a transverse cross-sectional (short axis) view using
ultrasound. A Tuohy-tip needle will be inserted beneath the ultrasound transducer and
directed until the needle tip is immediately adjacent to the target nerve. Local anesthetic
(1-3 mL, lidocaine 2%) will be injected. This will be repeated for the femoral nerve. Within
20 minutes of the second injection, the subject's limb pain level will be evaluated on the
0-10 NRS and if higher than at baseline prior to injection, the subject will NOT continue
with treatment and their participation in the study will terminate upon discharge.

Treatment group assignment (randomization). Remaining subjects will be allocated to one of
two possible treatments:

1. cryoneurolysis

2. sham cryoneurolysis (placebo control)

Randomization will be computer-generated and stratified by enrolling institution in randomly
chosen block sizes. Cryoneurolysis probes are available that either (1) pass nitrous oxide to
the tip inducing freezing temperatures; or, (2) vent the nitrous oxide at the base of the
probe so that no gas reaches the probe tip, resulting in no temperature change (PainBlocker,
Epimed, Farmers Branch, Texas). Importantly, these probes are indistinguishable in
appearance. Unmasking will not occur until statistical analysis is complete.

Intervention. The potential cryoneurolysis sites will be again cleansed with chlorhexidine
gluconate and isopropyl alcohol. With the same ultrasound transducer used to previously
administer local anesthetic, the target nerve will again be identified in a transverse
cross-sectional (short axis) view at or distal to the deposition of local anesthetic. A
cryoneurolysis device (PainBlocker, Epimed, Farmers Branch, Texas) will be inserted with the
appropriate randomization-designated probe (either active or sham/placebo) and nitrous oxide.
The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active
or sham) separated by 1-minute defrost periods. The process will be repeated with the same
treatment probe for the femoral nerve (e.g., both nerves will receive either active
cryoneurolysis or sham/placebo, and not a mix of the two possible treatments).

Optional crossover treatment. Four to 6 months following the initial treatment, subjects may
return for an optional repeated intervention procedure ("crossover") with the alternative
treatment (either active cryoneurolysis or sham/placebo), again in a double-masked fashion
using the same protocol as described for the initial intervention. The crossover treatment is
not required for study participation, as the primary analyses will include a parallel study
design for the initial intervention evaluated prior to any crossover treatment. This
crossover will not affect the primary analyses, which will involve a parallel group study
design and investigate the effects of cryoneurolysis within 4 months of the initial
intervention.

Outcome measurements (endpoints). The primary end point will be the difference in average
daily phantom pain intensity at baseline and 4 months following the initial intervention
(measured with the NRS as part of the Brief Pain Inventory). The primary analyses will
compare the two treatments (inter-subject comparisons) during the initial treatment period in
which half of the subjects will receive active cryoneurolysis and the other half a
sham/placebo treatment. Endpoints will be evaluated at baseline and post-treatment (Day 0),
Days 1 and 7; and Months 1, 2, 3, 4, and 12. These same time points through Month 4 will be
evaluated following the optional second (crossover) treatment.

Data collection. The questionnaires for all subjects-regardless of enrolling center-will be
administered by telephone from the University of California San Diego by research
coordinators specifically trained in these instruments' application, minimizing inter-rater
discordance. Staff masked to treatment group assignment will perform all assessments.

Inclusion Criteria:

- Adult patients of at least 18 years of age

- with a lower limb traumatic or surgical amputation at least 12 weeks prior to
enrollment distal to the hip (femoral head remaining)

- who experience at least moderate phantom limb pain-defined as a 3 or higher on the
Numeric Rating Scale (NRS; 0-10, 0= no pain; 10=worst imaginable pain)-at least daily
for the previous 2 months.

- accepting of a cryoneurolysis procedure

- willing to avoid both changes to their analgesic regimen as well as elective surgical
procedures from 1 month prior to and at least 4 months following the initial
cryoneurolysis procedure.

Exclusion Criteria:

- allergy to amide local anesthetics

- pregnancy

- incarceration

- inability to communicate with the investigators

- morbid obesity (body mass index > 40 kg/m2)

- possessing any contraindication specific to cryoneurolysis such as a localized
infection at the treatment site, cryoglobulinemia, cold urticaria and Reynaud's
Syndrome.
We found this trial at
6
sites
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Matthew Miller, MD
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Alparslan Turan, MD
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Cameron Smith, MD
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: Edward R Mariano, MD, MAS
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
San Diego, California 92093
Principal Investigator: Brian M Ilfeld, MD, MS
Phone: 858-534-1251
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Diego, California 92134
Principal Investigator: Carter Sigmon, MD
?
mi
from
San Diego, CA
Click here to add this to my saved trials